SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02961270

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Clinical Activity of Icotinib in Patients With Advanced Non-small-cell Lung Cancer Harbouring Uncommon EGFR Mutations: a Single-arm, Prospective, Phase 2 Study

This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation

NCT02961270 Non-small Cell Lung Cancer
MeSH: Lung Neoplasms Carcinoma, Non-Small-Cell Lung
HPO: Neoplasm of the lung Non-small cell lung carcinoma

1 Interventions

Name: Icotinib

Description: Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity

Type: Drug

icotinib


Primary Outcomes

Measure: progression-free survival

Time: 10 months

Secondary Outcomes

Measure: tumor response rate

Time: 2 months

Measure: overall survival

Time: 24 months

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 L858R

Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Non-small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- L858R ---

Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Inclusion Criteria: - Patients with stage IIIB/IV non-small cell lung cancer - Patients with uncommon epidermal growth factor receptor (EGFR) mutation - Targeted-therapy-naive patients - Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2 - Evaluable target lesions according to RECIST 1.1 for tumour response assessment Exclusion Criteria: - Wild-type EGFR - Positive 19 del and/or 21 L858R mutation - Previous treatment with EGFR TKIs such as gefitinib, erlotinib, and afatinib - Patients who have documented history of interstitial lung disease Non-small Cell Lung Cancer Lung Neoplasms Carcinoma, Non-Small-Cell Lung null --- L858R --- --- L858R ---



HPO Nodes


HPO:
Neoplasm of the lung
Genes 43
WT1 KRAS SLC22A18 STK11 IRF1 AKT1 C11ORF95 PRKN PPP2R1B ERBB2 TRPV3 TSC1 POU6F2 TSC2 EWSR1 RELA KEAP1 REST DIS3L2 SFTPA2 GPC3 MBTPS2 LMNA PTEN BRAF BRCA2 EGFR RB1 TRIP13 PDGFRB TERT SFTPC PIK3CA TRIM28 DICER1 MAP3K8 HPGD SLCO2A1 H19 TP53 NOTCH3 BAP1 WRN
Non-small cell lung carcinoma
Genes 2
TP53 BAP1